nach oben

Journal of Experimental & Clinical Cancer Research

Erschienen in:

Open Access 01.12.2023 | Research

Long-term exposure to house dust mites accelerates lung cancer development in mice

verfasst von: Dongjie Wang, Wen Li, Natalie Albasha, Lindsey Griffin, Han Chang, Lauren Amaya, Sneha Ganguly, Liping Zeng, Bora Keum, José M. González-Navajas, Matt Levin, Zohreh AkhavanAghdam, Helen Snyder, David Schwartz, Ailin Tao, Laela M. Boosherhri, Hal M. Hoffman, Michael Rose, Monica Valeria Estrada, Nissi Varki, Scott Herdman, Maripat Corr, Nicholas J. G. Webster, Eyal Raz, Samuel Bertin

Erschienen in: Journal of Experimental & Clinical Cancer Research | Ausgabe 1/2023

Abstract

Background

Individuals with certain chronic inflammatory lung diseases have a higher risk of developing lung cancer (LC). However, the underlying mechanisms remain largely unknown. Here, we hypothesized that chronic exposure to house dust mites (HDM), a common indoor aeroallergen associated with the development of asthma, accelerates LC development through the induction of chronic lung inflammation (CLI).

Methods

The effects of HDM and heat-inactivated HDM (HI-HDM) extracts were evaluated in two preclinical mouse models of LC (a chemically-induced model using the carcinogen urethane and a genetically-driven model with oncogenic Kras^G12D activation in lung epithelial cells) and on murine macrophages in vitro. Pharmacological blockade or genetic deletion of the Nod-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome, caspase-1, interleukin-1β (IL-1β), and C–C motif chemokine ligand 2 (CCL2) or treatment with an inhaled corticosteroid (ICS) was used to uncover the pro-tumorigenic effect of HDM.

Results

Chronic intranasal (i.n) instillation of HDM accelerated LC development in the two mouse models. Mechanistically, HDM caused a particular subtype of CLI, in which the NLRP3/IL-1β signaling pathway is chronically activated in macrophages, and made the lung microenvironment conducive to tumor development. The tumor-promoting effect of HDM was significantly decreased by heat treatment of the HDM extract and was inhibited by NLRP3, IL-1β, and CCL2 neutralization, or ICS treatment.

Conclusions

Collectively, these data indicate that long-term exposure to HDM can accelerate lung tumorigenesis in susceptible hosts (e.g., mice and potentially humans exposed to lung carcinogens or genetically predisposed to develop LC).

Additional file 1: Supplemental Fig. 1. Effect of chronic exposure to HDM in a urethane-induced LC model. A-F) WT C57BL/6 mice were treated i.n with HDM (n = 8), HI-HDM (n = 10), or with the vehicle (VEH, n = 9) and i.p with urethane as shown in Fig. 1A. A) Quantification of inflammatory cell infiltrates on H&E-stained lung sections as shown in Fig. 1D. B) The tumor multiplicity and C) the tumor area data presented in Fig. 1H–I were subdivided into male and female mice for the three experimental groups. D) Representative images of Wright-Giemsa staining of BALF cytospins. Magnification, 200x (overview panels), 400x (insets). E) BALF total and differential cell counts of BALF cytospins as shown in D. F) Correlation analysis of the number of monocytes/macrophages in the BALF with tumor multiplicity. The Pearson coefficient (R squared) and the corresponding P-value are shown. G) Representative pictures of H&E-stained lung sections of Rag1 KO mice treated i.n with VEH (n = 9) or HDM (n = 9), and i.p with urethane (0.6 mg/g of BW) as shown in Fig. 1A for WT mice. One lobe per mouse is shown. Arrowheads indicate tumors. Scale bars, 1 mm. H) Tumor multiplicity calculated on H&E-stained sections as shown in G. Data are presented as mean ± SEM. Statistical significance was assessed by one-way (A) or two-way (B, C, and E) ANOVA with post hoc Bonferroni’s test, linear regression using Pearson correlation (F), or two-tailed Student’s t-test (H). n.s: non-significant, * P < 0.05, ** P <0.01, *** P <0.001, **** P < 0.0001. Supplemental Fig. 2. Effect of chronic exposure to HDM in a Kras^G12D-driven LC model. A) Five-week-old Kras^G12D mice were treated i.n with VEH (n = 11) or HDM (n = 12) as indicated in this schematic overview of the study design. At 14 weeks of age and 72h after the last HDM challenge the mice were sacrificed and the BALFs and the lungs were harvested. B) Representative pictures of 4 lung lobes (dorsal view) of a VEH- and an HDM-treated mouse. Scale bars, 0.25 cm. C) Lung weight normalized to mouse body weight (BW). D) BALF total cell counts. E) Representative pictures of H&E-stained lung sections. The lower panels are the same images as the above panels after tumor area quantification using QuPath software. The area within the blue borders was considered positive for lung tumors. The right panels show the boxed region (ROI#1) at higher magnification with areas of alveolar/bronchiolar hyperplasia and numerous mononuclear inflammatory infiltrates. Scale bars, 2 mm (whole lungs) and 0.5 mm (ROI#1). F) Tumor multiplicity calculated on H&E-stained sections as shown in E upper panels. G) Tumor area calculated on H&E-stained sections as shown in E lower panels. H) Quantification of inflammatory cell infiltrates on H&E-stained lung sections of 18-week-old Kras^G12D mice treated i.n with VEH, HDM, or HI-HDM as shown in Fig. 2E. I) Representative pictures of H&E-stained lung sections showing the different types of lung lesions observed in 18-week-old Kras^G12D mice treated i.n with VEH, HDM, or HI-HDM as shown in Fig. 2E. Top left panels: Grade 1 lesion of AAH with lepidic growth pattern observed in a Kras^G12D mouse treated with VEH. Scale bars, 0.1 mm (overview panel and inset). Middle left panels: Grade 1 lesion of EH of a respiratory bronchiole with hyperproliferative cells in the alveolar compartment observed in a Kras^G12D mouse treated with VEH. Scale bars, 0.1 mm (overview panel and inset). Middle right panels: Grade 2 AD of the papillary type with uniform nuclei observed in a Kras^G12D mouse treated with VEH. Scale bars, 0.2 mm (overview panel) and 0.1 mm (inset). Right panels: Grade 3 AC of the papillary type with enlarged nuclei, prominent nucleoli, and some areas of tumor cell crowding (field of cells indicated by arrows) observed in a Kras^G12D mouse treated with HDM.Scale bars, 0.25 mm (overview panel) and 0.1 mm (inset).Data are representative of one experiment conducted in six independent cohorts of mice pooled together and are presented as mean ± SEM. Statistical significance was assessed by two-tailed Student’s t-test (C, D, F, and G) or one-way ANOVA with post hoc Bonferroni’s test (H). ** P <0.01, *** P <0.001, **** P <0.0001. Supplemental Fig. 3. Effect of chronic HDM exposure on the lung microenvironment. Kras^G12D mice were treated i.n with VEH or HDM (n = 3 mice/group) as shown in Fig. 2A and were sacrificed at day 61 (24h after the last i.n treatment). The lungs and the BALFs were recovered and single-cell suspensions were prepared for flow cytometry analyses. A) Representative flow cytometry plots of an HDM-treated mouse illustrating the gating strategy for the flow cytometry analyses. First, dead cells and debris were excluded based on forward scatter area (FSC-A) and side scatter area (SSC-A) values, then live single cells were gated based on forward scatter height (FSC-H) and FCS-A values.Macrophages (MΦ) were then identified as CD11b⁺CD11c^–F4/80⁺ cells. B) Representative dot plots of cells expressing the pan-myeloid marker CD11b in the BALFs of VEH- and HDM-treated mice. C) Frequencies and D) absolute numbers of CD11b⁺ cells as shown in B. E) Representative histograms showing intracellular levels of pro-IL-1β in CD11b⁺ cells gated as in B in the BALFs of VEH- and HDM-treated mice. F) Frequencies and G) absolute numbers of pro-IL-1β⁺CD11b⁺ cells as shown in E. H) Representative dot plots of MDSCs (identified as CD11b⁺ cells gated as in B expressing F4/80 and intermediate levels of Gr-1) in the BALFs of VEH- and HDM-treated mice. I) Frequencies and J) absolute numbers of MDSCs as shown in H. K) Representative histograms showing PD-1 expression levels on CD11b^– cells gated as in A. L) Frequencies and M) absolute numbers of PD-1⁺CD11b^– cells as shown in K. Data are presented as mean ± SEM. Statistical significance was assessed by two-tailed Student’s t-test. n.s: non-significant, * P < 0.05, ** P < 0.01. Supplemental Fig. 4. Effect of HDM and other allergens on IL-1β secretion by BMDMs. A) Schematic overview of the BMDM culture system. Bone marrow (BM) cells were harvested from WT, Nlrp3, Casp1, or Il1b KO mice and were differentiated into BMDMs in presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) for 7 days. BMDM (identified as CD11b⁺F4/80⁺ cells) purity was assessed by flow cytometry and was ~80% as shown in a representative dot plot. BMDMs were then stimulated for 24h with LPS, HDM, or other allergens, and ATP was added to each well for the last hour of culture. The supernatants were collected and the levels of IL-1β or TNF were analyzed by ELISA. B) WT BMDMs were pretreated for 1h at 37°C with an NLRP3 inhibitor (MCC950) or with a caspase-1 inhibitor (VX-765) at concentrations of 100 nM and 10 μM, respectively before being stimulated with HDM (200 μg/mL) and ATP (5 mM) as shown in A, and the levels of IL-1β or C) TNF in the supernatants were analyzed by ELISA. D) WT BMDMs were stimulated with the indicated concentrations of HDM Dermatophagoides pteronyssinus (DP) as in B and C, HDM Dermatophagoides farinae (DF), German cockroach (CR), ragweed pollen (RW), the fungi Candida albicans (CA) or Alternaria alternata (AA) and ATP (5 mM) as shown in A. The supernatants were collected and IL-1β production was analyzed by ELISA. IL-1β level in the supernatants of DP-treated cells was used as a reference and assigned to 100%. Data are representative of two (B and C) or three (D) independent experiments performed in triplicate and are presented as mean ± SEM. Statistical significance was assessed by one-way ANOVA with post hoc Bonferroni’s test. n.s: non-significant, * P < 0.05, ** P < 0.01, **** P < 0.0001. Supplemental Fig. 5. Effect of chronic exposure to HDM DF or ovalbumin on lung tumor development. A) Kras^G12D mice were treated i.n with VEH (n = 4), DF (n = 9), or ovalbumin (OVA, n = 6) as indicated in this schematic overview of the study design. B) Representative pictures of H&E-stained lung sections of mice in the three different groups. Scale bars, 2 mm. C) Tumor multiplicity calculated on H&E-stained sections as shown in B. Data are presented as mean ± SEM. Statistical significance was assessed by one-way ANOVA with post hoc Bonferroni’s test. n.s: non-significant, * P < 0.05, ** P < 0.01. Supplemental Fig. 6. Effect of IL-1β, CCL2, or NLRP3 neutralization in Kras^G12D mice. A) Kras^G12D mice were treated i.n with VEH or HDM and i.p with an anti-IL-1β, an anti-CCL2, or with the isotype control (ctrl) antibody (Ab), or with the NLRP3 inhibitor MCC950 as indicated in this schematic overview of the study design. B) Representative pictures of H&E-stained lung sections of mice treated with VEH + MCC950 (n = 7) or HDM + MCC950 (n = 11). Scale bars, 2 mm. C) Tumor multiplicity calculated on H&E-stained sections as shown in B. D) Tumors on H&E-stained sections as shown in B were classified into three grades (Grade 1, AAH and EH; Grade 2, AD; Grade 3, AC) and each grade was expressed as a percentage of the total. Data are representative of one experiment conducted in three independent cohorts pooled together (B–D) and are presented as mean ± SEM. Statistical significance was assessed by two-tailed Student’s t-test (C) or two-way ANOVA (D) with post hoc Bonferroni’s test. n.s: non-significant. Supplemental Fig. 7. HDM induces CCL2 production in the BALF of Kras^G12D mice and IL-1β neutralization inhibits this effect. A) ELISA analysis of CCL2 production in BALF recovered from Kras^G12D mice treated i.n with VEH, HDM, or HI-HDM as shown in Fig. 2A (n = 4 mice/group) or B) treated i.n with VEH or HDM and i.p with the anti-IL-1β or the isotype ctrl Ab as shown in Supplemental Fig. 6A (n = 3 mice/group). Data are representative of one experiment conducted twice independently and are presented as mean ± SEM. Statistical significance was assessed by one-way ANOVA with post hoc Bonferroni’s test. n.s: non-significant, * P< 0.05, ** P < 0.01, *** P< 0.001. Supplemental Fig. 8. Antibody validation for mIF and IHC staining. A) mIF staining of a mouse spleen section showing strong F4/80 and Ki-67 immunoreactivity. As expected, no PanCK was observed in the spleen. B) No background or non-specific binding was observed in the spleen negative control in the absence of the primary Abs. DAPI is shown for context. C) Positive control slide images using human tonsils showing strong PanCK and Ki-67 immunoreactivity. The F4/80 antibody does not work for human tissue. D) No background or non-specific binding was observed in the tonsil negative control in the absence of the primary Abs. DAPI is shown for context. E) Negative controls on a mouse lung section using secondary anti-Tag fluorescent Abs only. No staining was observed in absence of primary Abs. However, some autofluorescence was detected in the PanCK/CL550 (Cy3) channel from the heart tissue and red blood cells. Overlay (top) and single colors (bottom). DAPI nuclear staining (blue), F4/80 (magenta), Ki-67 (cyan) and PanCK (yellow). Scale bars, 0.25 mm (spleen and tonsil samples) and 2 mm (lung samples). F) IHC staining of a mouse lung lobe showing nuclear staining for TTF-1 in airway epithelial cells, including alveolar pneumocytes and club cells. No staining was observed in inflammatory cell infiltrates surrounding the bronchi and bronchioles. Scale bars, 1mm (upper panel) and 0.1 mm (inset). Data are representative of one (F) or two (A–G) independent experiments. Supplemental Fig. 9. Proposed model for the lung tumor-promoting effect of HDM. Chronic i.n instillation of HDM extracts triggers the activation of the NLRP3 inflammasome and caspase-1 in lung macrophages (MΦ, identified as CD11b⁺CD11c^–F4/80⁺ cells), which leads to increased secretion of IL-1β in the lung microenvironment and persistent lung inflammation. In addition, HDM induces the accumulation of PD-1⁺-myeloid cells (identified as PD-1⁺CD11b⁺ cells) and myeloid-derived suppressor cells (MDSCs, identified as Gr-1⁺CD11b⁺ cells) in the lungs, which are known to inhibit anti-tumor immunity and to promote tumor cell proliferation. Neutralization of NLRP3, IL-1β, or CCL2, which could contribute to the recruitment of bone marrow (BM)-derived circulating monocytes and to the replenishment and pro-inflammatory phenotype of lung MΦ, as well as treatment with budesonide, which has anti-inflammatory and anti-proliferative properties, all inhibit the tumor-promoting effect of HDM. Finally, NLRP3 activation, IL-1β production, and the pro-tumorigenic effect of HDM were also significantly decreased but not completely abolished by heat treatment of the HDM extracts, suggesting that both heat-sensitive (e.g., proteolytic enzymes derived from the mites’ digestive system) and -insensitive (e.g., heat-insensitive proteases, LPS, and/or carbohydrates such as chitin) factors in HDM extract contributed to these effects. This schematic representation was created with BioRender.com and Servier Medical Art. Supplemental Table 1. Reagents used in this study. Supplemental Table 2. Oligonucleotides used for RT-qPCR analysis.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13046-022-02587-9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

AAH

Atypical adenomatous hyperplasia

Antibody

Adenocarcinoma

Adenoma

ATP

Adenosine triphosphate

BALF

Broncho-alveolar lavage fluid

BMDM

Bone marrow-derived macrophage

Body weight

C57BL/6 strain of mice

Casp-1

Caspase-1

CCSP

Clara cell secretory protein

Cytokeratin

CLI

Chronic lung inflammation

DAPI

4′,6-Diamidino-2-phenylindole blue-fluorescent DNA stain

Dermatophagoides pteronyssinus

Dermatophagoides Farinae

EGFR

Epidermal growth factor receptor

Epithelial hyperplasia

ELISA

Enzyme-linked immunosorbent assay

Endotoxin units

GM-CSF

Granulocytes macrophage colony-stimulating factor

H&E

Hematoxylin and eosin

HDM

House dust mites

Heat-inactivated

ICS

Inhaled corticosteroid

Immunofluorescence

IHC

Immunohistochemistry

Interleukin

i.n

Intranasal/intranasally

i.p

Intraperitoneal/intraperitoneally

Knockout

Kras

Kirsten rat sarcoma viral oncogene homolog

Lung cancer

LPS

Lipopolysaccharide

MDSC

Myeloid-derived suppressor cell

MΦ

Macrophage

NF-κB

Nuclear factor-kappa B

NLPR3

Nod-like receptor family pyrin domain-containing protein 3

NSCLC

Non-small cell lung cancer

n.s

Non-significant

PAMPs

Pathogen-associated molecular patterns

PanCK

Pan-cytokeratin

PBS

Phosphate-buffered saline

PCNA

Proliferating cell nuclear antigen

PD-1

Programmed cell death protein 1

qPCR

Quantitative real-time PCR

RBC

Red blood cell

ROI

Region of interest

Room temperature

SEM

Standard error of the mean

STAT3

Signal transducer and activator of transcription 3

TAM

Tumor-associated macrophage

TME

Tumor microenvironment

TNF

Tumor necrosis factor

VEGF

Vascular endothelial growth factor

VEH

Vehicle

Background

Lung cancer (LC) is the leading cause of cancer death worldwide [1], with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases [2]. Several lines of evidence support the hypothesis that individuals with certain chronic inflammatory lung diseases have a higher risk of developing LC independently of their smoking status [3, 4]. Indeed, chronic obstructive pulmonary disease (COPD) is a strong risk factor for LC [5, 6] and an increasing number of studies have demonstrated the positive association between other chronic inflammatory lung diseases and LC [7‐11]. Chronic lung inflammation (CLI) as occurring in asthma could increase the risk of developing LC [9, 12, 13] but the exact mechanism by which CLI promotes LC remains unclear. CLI is characterized by diverse molecular and cellular changes, and it is not known which of these changes are essential for the subsequent increased risk of LC. In addition, we do not know which types or subtypes of lung inflammation are causing LC. Therefore, identifying the critical steps by which CLI promotes LC development could provide important new insights into the prevention and treatment of LC.

To better understand the relationship between CLI and LC, we evaluated in this preclinical study the effects of chronic exposure to house dust mites (HDM) in two different mouse models of NSCLC. HDM is a common indoor aeroallergen associated with the development of asthma [14] that can induce CLI and lung epithelial damage [14‐17]. Thus, we hypothesized that chronic exposure to HDM could accelerate LC development in susceptible hosts through the induction of pro-inflammatory cytokines such as IL-1β [18‐20]. At the cellular level, IL-1β is known to stimulate angiogenesis in the tumor microenvironment (TME) [21], and to induce the production of IL-6 and IL-17A, which are well-established mediators of tumor growth. These cytokines are also involved in the recruitment of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that can promote tumor development and progression [22, 23].

In 2017, the CANTOS (Canakinumab ANti-inflammatory Thrombosis Outcomes Study) clinical trial evaluated the effect of a neutralizing anti-IL-1β antibody (Ab) (canakinumab) in patients with atherosclerosis prone to cardiovascular events and made the serendipitous observation that IL-1β blockade significantly reduced LC incidence and mortality [24]. This study provided the first evidence of anti-IL-1β therapy as a potential treatment for LC and has led to the design of several clinical trials that are currently exploring IL-1β as a therapeutic target in NSCLC [25‐27]. However, among the follow-up studies, two recent clinical trials studying the effect of canakinumab in combination with immunotherapy (anti-PD-1 Ab) or chemotherapy in metastatic NSCLC could only demonstrate potential clinical benefits in certain subgroups of patients based on the baseline of inflammatory biomarkers (e.g., C-reactive protein) [27, 28]. Thus, these data support further evaluation of anti-IL-1β therapy in LC and indicate that predictive biomarkers are needed to identify the right patient population.

In this study, we identified that chronic exposure to HDM activates the NLRP3 inflammasome in macrophages, increases the production of IL-1β in the lungs, induces a pro-tumor lung microenvironment, and accelerates LC development and progression in two different mouse models. Together, these data suggest that the effect of HDM is not limited to the induction of allergic lung inflammation and that long-term exposure to HDM may also represent an environmental risk factor for LC.

Materials and methods

Animals

Wild-type (WT) C57BL/6 J (JAX, Strain# 000664), Nlrp3 KO (JAX, Strain# 021302), and Rag1 KO mice (JAX, Strain# 002216), both on the C57BL/6 J background, were originally purchased from the Jackson Laboratory (JAX). Initial breeding pairs of Il1b KO mice (JAX, Strain# 034447) backcrossed to C57BL/6 J for over 10 generations were kindly provided by Dr. Wai Wilson Cheung, Dr. Robert Mak, and Dr. Hal Hoffman (UCSD). Initial breeding pairs of Casp1 KO mice (JAX, Strain# 016621) on the C57BL/6 background were a gift from Dr. Richard Flavell (Yale University). Initial breeding pairs of CCSP^Cre (JAX, Strain# 036525) [29] and LSL-Kras^G12D (JAX, Strain# 008179) [30] mice, both on the C57BL/6 background, were a gift from Dr. Seon Hee Chang (The University of Texas MD Anderson Cancer Center). For the generation of Kras^G12D mice, CCSP^Cre± mice were intercrossed with LSL-Kras^G12D± as detailed in the Kras^G12D-driven LC model section. All the mice were bred in our vivarium under specific pathogen-free (SPF) or enhanced-barrier SPF (Rag1 KO) conditions for more than 6 months and were genotyped before they were used in any experiments. All the mice were kept on a 12-h light and 12-h dark cycle with a standard chow diet and water.

Chemical compounds

Urethane (Sigma-Aldrich, Cat# U2500) was resuspended in 0.9% sodium chloride solution (BD, Cat# 306546) and passed through a 0.22 µm sterile filter before being administered to the mice. Budesonide (Tocris, Cat# 2671) and VX-765 (Selleckchem, Cat# S2228) were reconstituted in DMSO, MCC950 (Selleckchem, Cat# S7809) was resuspended in sterile PBS, and all compounds were aliquoted, and stored at -80 °C until used.

Allergen extracts

HDM extracts were generated by Greer Laboratories as follows: whole bodies of Dermatophagoides pteronyssinus (DP) or Dermatophagoides farinae (DF) were extracted with 0.01 M ammonium bicarbonate (1:20, w/v) overnight at 2–8 °C. The crude extract, recovered after centrifugation, was dialyzed against pyrogen-free water, sterilized using a 0.22-µm membrane filter, and lyophilized under aseptic conditions. Lyophilized extracts of HDM DP (Cat# XPB82D3A2.5 or XPB82D3A25) or DF (Cat# XPB81D3A2.5) were resuspended based on their total protein content at 2 mg/mL in sterile 0.9% sodium chloride solution (BD, Cat# 306546) for in vivo experiments or at 10 mg/mL in sterile PBS (Thermo Fisher Scientific, Cat# 14190144) for in vitro experiments, and were aliquoted and stored at -80 °C until used. When indicated, HDM DP was heat-inactivated (HI-HDM) for 1 h at 95ºC as previously described [31]. HDM and HI-HDM extracts were prepared from the same lot of HDM in all studies comparing their effects in vitro or in vivo. Other allergens used in this study include German cockroach (CR, Cat# XPB46D3A4), ragweed pollen (RW, Cat# XP56D3A2.5), Candida albicans (CA, Cat# XPM15D3A5), and Alternaria alternata (AA, Cat# XPM1D3A2.5). All the allergen extracts were purchased from Greer Laboratories, resuspended based on their total protein content at 10 mg/mL in sterile PBS, and were aliquoted and stored at -80 °C until used.

Intranasal instillations

In the urethane model, mice were sensitized intranasally (i.n) under light anesthesia (isoflurane) on days 0 and 10 with HDM or HI-HDM (50 μg/50 μL/mouse) or with the control vehicle (VEH; 0.9% sodium chloride, BD, Cat# 306546, 50 μL/mouse), challenged i.n 2x/week for 10 weeks and then 1x/week for an additional 16 weeks with HDM or HI-HDM (12.5 μg/50 μL/mouse) or VEH (50 μL/mouse). In the Kras^G12D model, mice were sensitized i.n on day 0 with HDM, HI-HDM, or OVA (50 μg/30 μL/mouse) or VEH (30 μL/mouse), challenged i.n 2x/week for 4 weeks and 1x/week for 4 weeks with HDM, HI-HDM, or OVA (12.5 μg/30 μL/mouse) or VEH (30 μL/mouse), and then either euthanized (14-week-old time point) of left untreated for an additional 4 weeks (18-week-old time point). When indicated, Kras^G12D mice were treated i.n with budesonide (5 μg/mouse in 30 μL VEH with 0.5% DMSO) or DMSO (30 μL VEH with 0.5% DMSO/mouse) 3x/week and 30 min before each HDM or VEH i.n treatment and then 3x/week for an additional 4 weeks.

Urethane-induced LC model

Age- and sex-matched C57BL/6 WT or Il1b KO mice were injected intraperitoneally (i.p) with urethane (Sigma-Aldrich, Cat# U2500; 1 mg/g of BW) 1x/week for 10 consecutive weeks (tumor initiation stage) followed by a 16-week resting period (tumor promotion stage) as previously described [32]. Due to their observed increased susceptibility to urethane, age- and sex-matched C57BL/6 Rag1 KO mice were treated with a lower dose of urethane (0.6 mg/g of BW) but with the same number of i.p injections and for the same duration. Twenty-six weeks after the first urethane injection and 72 h after the last i.n challenge, the mice were euthanized by CO2 asphyxiation, and the blood, the lungs, and the BALF were collected. One lung lobe of the right lung was removed, snap-frozen in liquid nitrogen, and stored at -80 °C until further processing. The remaining 4 lung lobes were fixed in 10% buffered formalin for 24 h and stored in histological grade 70% ethanol until paraffin embedding.

Kras^G12D-driven LC model

We crossed the LSL-Kras^G12D strain [30], which carries a Lox-Stop-Lox (LSL) sequence followed by the Kras^G12D point mutation allele commonly associated with human cancer, with a transgenic mouse expressing the Cre recombinase under the control of the Clara cell secretory protein (CCSP) promoter [29], thereby allowing the expression of the mutant KRAS oncogenic protein specifically in lung club cells (formerly known as Clara cells). The resulting CCSP^Cre±Kras^G12D± mice (hereafter referred to as Kras^G12D mice) were treated from 5 to 14 or 18 weeks of age i.n with HDM, HI-HDM, OVA, or VEH. When indicated, mice were injected i.p with either a neutralizing anti-mouse IL-1β Ab (BioXCell, Cat# BE0246), a neutralizing anti-mouse CCL2 Ab (BioXCell, Cat# BE0185), or with the isotype control Ab (BioXCell, Cat# BE0091) diluted in InVivoPure pH 7.0 Dilution Buffer (BioXCell, Cat# IP0070) and administrated at the same dose (50 μg/100 μL/mouse) and periodicity as previously described [33, 34] or with MCC950 at the dose of 20 mg/kg [35], 1 h before each HDM or VEH i.n treatment and then once a week for an additional 4 weeks. Finally, 24 or 72 h after the last i.n challenge (14-week-old time point) or 4 weeks after the last i.n challenge and 72 h after the last i.p injection (18-week-old time point), the mice were euthanized by CO2 asphyxiation and the blood, the BALF, and the lungs were harvested. After ligation, one lung lobe of the right lung was removed, snap-frozen in liquid nitrogen, and stored at -80 °C until further processing. The remaining 4 lung lobes were fixed by intratracheal instillation and immersion in 10% buffered formalin solution for 24 h and were stored in histological grade 70% ethanol until paraffin embedding.

BALF cellularity analysis

Mouse lungs were inflated with 1 ml of PBS and BALF was recovered and spun down. Total cell counts were performed manually on a hemocytometer and 1 × 10⁵ cells into 100 μL of PBS/2% fetal bovine serum (FBS) were cytocentrifuged (Cytospin 2, Shandon) onto microscope slides for 3 min at 500 rpm. The air-dried cytospin preparations were stained by Wright-Giemsa stain (Thermo Fisher Scientific) for 3 min at RT and rinsed with deionized water. The slides were mounted in Cytoseal 60 (Thermo Fisher Scientific) and were examined using light microscopy. Differential cell counts were performed according to standard protocols [36].

Histological analysis

After fixation, the lung samples were brought in histological grade 70% ethanol to the UCSD Moores Cancer Center Tissue Technology Shared Resource for paraffin embedding and sectioning. The fixed lungs were cut into 4–6-μm sections, placed on glass slides, and stained with hematoxylin (Thermo Fisher Scientific, Cat# 7221) and eosin (Thermo Fisher Scientific, Cat# 7111) (H&E) on a Gemini AS slide stainer (Thermo Fisher Scientific) using standard staining procedures. H&E slides were scanned on a Hamamatsu Nanozoomer (Hamamatsu Photonics) or an Aperio AT2 slide scanner (Leica Biosystems), digitized, and whole-slide images were used for tumor assessments. Tumor counts were performed using ObjectiveView (Objective Pathology) or QuPath [37] software in a blinded fashion following expert guidance provided by two board-certified pathologists and current recommendations for the classification of proliferative pulmonary lesions in mice [38]. The tumor multiplicity (i.e., the number of lung lesions per mouse) was calculated on one (Kras^G12D model) or two (urethane model) H&E-stained step sections. (100 μm apart) of 4 lung lobes for each mouse. In the urethane model, ADs and ACs showed ovoid shape. Therefore, we used the following formula to calculate their surface area: major radius x minor radius x π. The tumor area was calculated as the sum of AD and AC surface areas for each mouse and was expressed in mm². Because of the diffuse infiltrative nature of the lung lesions in the Kras^G12D model, the tumor area was determined using Image-Pro Premier (Media Cybernetics) or QuPath software and was expressed as a percentage of the lung surface area or in mm². To evaluate tumor progression in Kras^G12D mice, we employed a 3-stage grading system adapted from [39] with epithelial hyperplasia (EH) and atypical adenomatous hyperplasia (AAH) as grade 1, adenomas (ADs) with well-circumscribed borders and uniform nuclei as grade 2, adenocarcinomas (ACs) with enlarged nuclei, prominent nucleoli, scattered mitotic figures and areas of cell crowding as grade 3. The histological architecture of the lesions was classified as either lepidic (alveolar/bronchiolar hyperplasia), papillary, solid, or mixed papillary and solid (ADs or ACs). The criteria for differentiation between ADs and ACs were practical and were made by size, demarcation of the tumor margins, and cytological atypia [38]. The amount of inflammatory cell infiltrates on H&E-stained lung sections was scored in a blinded fashion using an inflammation score from 0 to 4 adapted from [40]. The inflammation scores refer to absent “0”, very little amount “1” (< 10% of the total surface area of the lungs), little amount “2” (10–25% of the total surface area of the lungs), moderate amount “3” (25–50% of the total surface area of the lungs), and severe amount “4” (> 50% of the total surface area of the lungs) of inflammatory cell infiltrates.

Immunohistochemistry and immunofluorescence staining

Monoplex immunohistochemistry (IHC) was performed using standard staining procedures as previously described [41]. Briefly, 4–6-μm mouse lung FFPE sections were cleared, dehydrated and antigen retrieval was performed in Antigen Unmasking Solution (Vector Labs, Cat# H-3301) at 95ºC for 30 min. Blocking was done using 3% Donkey serum in TBST for 10 min. The slides were then incubated with a rabbit anti-TTF-1 Ab (Abcam, Cat# ab76013, 1:200 dilution) for 1 h at RT, followed by detection with a goat anti-rabbit IgG-HRP (Cell IDx, Cat# 2RH-100) for 30 min at RT and DAB Chromogen (VWR, Cat# 95041-478) for 5 min. Counterstaining was performed with Mayer’s Hematoxylin (Sigma-Aldrich, Cat# 51275) for 5 min and mounting was done with a xylene-based mountant. For multiplex immunofluorescence (mIF), mouse lung FFPE sections were stained with a custom UltraPlex panel from Cell IDx (San Diego, CA). Briefly, heat-induced epitope retrieval was performed manually using a pressure cooker at a high setting (~ 120ºC) for 15 min in sodium citrate buffer, pH 6.0. All primary and secondary conjugates were created at Cell IDx (see Supplemental Table 1). Exposure times were identical for all samples. Mouse spleen and human tonsil FFPE sections were used as positive and negative controls and were provided by Cell IDx. Each primary Ab-Tag conjugate was previously tested by monoplex and multiplex on mouse spleen and/or human tonsil. Finally, the slides were scanned on an Aperio VERSA (mIF) or an Aperio AT2 (monoplex IHC) (Leica Biosystems). Image adjustments and data analysis were performed using QuPath software. F4/80 and Ki-67 positive cells were quantified using QuPath’s positive cell detection tool following published methods [37] and statistical analysis was performed in Prism (GraphPad Software).

Flow cytometry analysis

Lung single-cell suspensions were prepared as previously described [42, 43]. Briefly, mice lungs were perfused by cardiac perfusion using 1 mM EDTA containing HBSS after the removal of BALF cells by lavage with PBS. Lung tissues were then incubated at 37 °C for 30 min in the digestion solution (0.5 mg/mL collagenase type IA and 20 μg/mL DNase I in HBSS containing 5% FCS, 100 U/ml penicillin, and 100 μg/mL streptomycin) and the cell suspensions were passed through a 100 μm strainer. Lung single-cells or BMDMs, when indicated, were resuspended at the desired concentration (i.e., 1 × 10⁶ into 100 μL of PBS/2% FBS in 96-well round-bottom plates) in presence of anti-mouse CD16/CD32 (Fc Block, BioLegend, Cat# 101320) Ab and were stained for 30 min at 4ºC in the dark using Abs (all 1:100 dilution) against mouse CD11b (BioLegend, Cat# 101216), CD11c (BioLegend, Cat# 117310), F4/80 (BioLegend, Cat# 123110), Gr-1 (BioLegend, Cat# 108412), and PD-1 (Thermo Fisher Scientific, Cat# 12-9985-81). After surface staining, the cells were washed, fixed in IC Fixation Buffer (Thermo Fisher Scientific, Cat# 00–8222-49), permeabilized in Permeabilization Buffer (Thermo Fisher Scientific, Cat# 00–8333-56), and stained with an Ab (1:150 dilution) against pro-IL-1β (Thermo Fisher Scientific, Cat# 11-7114-80) for 30 min at 4ºC in the dark. Cells were washed and analyzed on an Accuri C6 flow cytometer (BD Biosciences). Data were computed using FlowJo software (Tree Star).

Immunoblotting

To evaluate protein expression by immunoblot, 30 mg of lung tissue or 1 × 10⁶ BMDMs were homogenized or lysed, respectively, in RIPA buffer (Thermo Fisher Scientific, Cat# 89,900) supplemented with protease inhibitors (MedChemExpress, Cat# HY-K0011) for 5 min on ice. The protein concentration was determined with a protein-quantification kit (Bio-Rad). Protein samples (10 μg/lane) were separated through SDS polyacrylamide gel electrophoresis (4–12% gradient, Invitrogen) and then transferred to PVDF membranes (Millipore). Membranes were blocked with 5% BSA/0.3% Tween 20 in PBS for 45 min at RT and incubated overnight at 4ºC with the following primary Abs (all 1:1000 dilution): Armenian hamster anti-mouse/rat/hamster IL-1β (Santa Cruz Biotechnology, Cat# sc-12742) for lung tissues, rabbit anti-mouse IL-1β (Cell Signaling Technology, Cat# 12426) for BMDMs, mouse anti-mouse/rat caspase-1 p20 (Santa Cruz Biotechnology, Cat# sc-398715), rabbit anti-mouse/human NLRP3 (Cell Signaling Technology, Cat# 15101), and mouse anti-mouse β-Actin (Sigma-Aldrich, Cat# A5316). The blots were washed and incubated for 45 min at RT with their corresponding HRP-conjugated secondary Abs (1:2000 to 1:10,000 dilution): mouse anti-Armenian hamster IgG-HRP (Santa Cruz Biotechnology, Cat# sc-2789), goat anti-rabbit IgG-HRP (Cell Signaling Technology, Cat# 7074), and goat anti-mouse IgG-HRP (BioLegend, Cat# 405306) and developed in SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Cat# 34577) according to the manufacturer’s instructions. ChemiDoc Imaging System (Bio-Rad) was used for detection and ImageJ software was used for densitometric measurements.

In vitro macrophage assays

BMDMs were isolated from WT, Nlrp3 KO, Casp1 KO, and Il1b KO mice using standard protocols as previously described [43]. Briefly, harvested bone marrow cells were cultured for 6 days in RPMI medium supplemented with 10% FBS, L-Glutamine, 1 × penicillin/streptomycin, and recombinant mouse GM-CSF (BioLegend, Cat# 576,302, 10 ng/mL). After 6 days, the adherent cells were collected, re-plated at 1 × 10⁶ cells per mL in 24- or 96-well plates, and were allowed to adhere to the plates for 24 h. BMDM (CD11b⁺F4/80⁺) purity was routinely checked by flow cytometry and was ~ 80%. BMDMs were then incubated with indicated concentrations of allergens or lipopolysaccharide (LPS, Sigma-Aldrich, Cat# L2630, 100 ng/mL) for 24 h. ATP (Sigma-Aldrich, Cat# A7699, 5 mM) was added to each cell culture well for the last hour of incubation. Following these treatments, the supernatants were collected and cytokine levels were assessed by ELISA. LPS + ATP was used as a positive control for NLRP3 activation and IL-1β release. When indicated, BMDMs were pretreated with a caspase-1 inhibitor (VX-765, Selleckchem, Cat# S2228) or with an NLRP3 inhibitor (MCC950, Selleckchem, Cat# S7809) at concentrations of 10 μM and 100 nM, respectively, for 1 h at 37 °C. RAW 264.7 cells (ATCC, Cat# TIB-71) were cultured in DMEM medium supplemented with 10% FBS and 1 × penicillin/streptomycin and were stimulated with HDM as indicated above for BMDMs.

RT-qPCR analysis

Isolation of total RNA from lung tissues or BMDMs was carried out with the PureLink RNA Mini Kit (Thermo Fisher Scientific, Cat# 12183018A) following the manufacturer’s protocol. One μg of RNA sample was used for reverse transcription (RT) and cDNA synthesis using qScript cDNA SuperMix (Quanta Biosciences, Cat# 95048). Quantitative real-time PCR (qPCR) was performed on a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, Cat# A28137) using PowerUp SYBR Green Master Mix (Thermo Fisher Scientific, Cat# A25742) according to the manufacturer’s instructions. Samples were run in triplicate and normalized to Krt19 or Gapdh gene expression as indicated in the figure legends. qPCR primers for specific target genes were designed based on their reported sequences and synthesized by Integrated DNA Technologies (IDT) Technologies. See Supplemental Table 2 for a list of the oligonucleotide sequences.

ELISA

The levels of IL-1β, TNF, or CCL2 in BMDM culture supernatants, in the BALF, or lung tissue homogenates were determined using target-specific ELISA kits (see Supplemental Table 1) and following the manufacturers' instructions.

Graphical illustrations

Graphical illustrations were created using BioRender (https://biorender.com) and Servier Medical Art (https://smart.servier.com).

Statistics

Sample sizes for in vivo studies were determined based on preliminary studies and the variability of the LC models used. All animal studies were adequately powered to achieve statistically significant results with the smallest number of animals. The number of mice per group and the level of replication for each in vitro and in vivo experiment are mentioned in the figure legends. Both male and female mice were used in this study. The effects reported were observed in a sex-independent manner and were similar in single- and co-housed mice. Age- and sex-matched mice were randomly assigned to treatment groups. Graphical representations were generated using Prism (GraphPad Software) and data are presented as mean ± SEM. The statistical significance between two groups was determined using unpaired Student t-tests with two-tailed P-values. The statistical significance between more than two groups was determined using one- or two-way analysis of variance (ANOVA) with post hoc Bonferroni’s tests. P-values of less than 0.05 were considered statistically significant. All statistics were computed using Prism (GraphPad Software).

Results

Chronic exposure to HDM accelerates LC development and progression in a urethane-induced LC model

To evaluate the effect of chronic HDM exposure on LC development, we first employed a chemically-induced mouse model of LC using the carcinogen urethane [44]. In both sensitive and resistant strains of mice, urethane induces broncho-alveolar ADs and less frequent ACs with histological features observed in NSCLC [45]. We used a previously established protocol that was shown to overcome the resistance of C57BL/6 mice [32] and examined whether chronic i.n instillation of HDM makes WT C57BL/6 mice more sensitive to urethane-induced lung tumorigenesis. Because HDM is an allergenic mixture that contains multiple proteases that can provoke lung epithelium damage [15], we compared the effects of HDM and heat-inactivated HDM (HI-HDM, 1 h at 95ºC), which denatures its proteins and inactivates its proteolytic activities [31] to those of the control vehicle (VEH) (Fig. 1A). Gross examination of the lungs revealed that mice treated with urethane and HDM or HI-HDM developed lung inflammation as indicated by the enlarged lungs (Fig. 1B) and the increased lung weight (Fig. 1C) as compared to mice treated with urethane and VEH. In addition, mice treated with urethane and HDM demonstrated severe diffuse perivascular/peribronchiolar inflammation with numerous inflammatory cell infiltrates including abundant macrophages surrounding many airways throughout the majority of the lung lobes as shown on H&E-stained lung sections (Fig. 1D) and at higher magnification in the region of interest (ROI) #1 (Fig. 1E). These histopathological features were observed to a lesser degree in mice treated with urethane and HI-HDM and were almost absent in mice treated with urethane and VEH (Fig. 1D and Supplemental Fig. 1A).

We next evaluated lung tumor development in the three experimental groups. Histopathological evaluation of the H&E-stained lung sections revealed that in all the groups, most lesions have the characteristics of alveolar/bronchiolar ADs with predominantly papillary morphology as shown in ROI#2 (Fig. 1E). One hundred percent of the mice treated with urethane and HDM or HI-HDM developed ADs whereas the incidence was 88.9% in mice treated with urethane and VEH. Interestingly, 25% of the mice treated with urethane and HDM also developed ACs characterized by enlarged nuclei, prominent nucleoli, and scattered mitotic figures as shown in ROI#3 (Fig. 1F), which were not observed in mice of the other experimental groups. Immunohistochemistry (IHC) analysis showed that these lesions are positive for thyroid transcription factor-1 (TTF-1), a typical marker of ACs [46] (Fig. 1G). Mice treated with urethane and HDM showed an increased number of lung lesions, which include ADs and ACs, and an increased tumor area as compared to mice treated with urethane and VEH (Fig. 1D, H–I). Interestingly, this was not observed in mice treated with urethane and HI-HDM, which had similar tumor multiplicity and tumor area to that found in VEH-treated mice (Fig. 1D, H–I). In line with these data, we observed an increased expression of several genes involved in cell proliferation such as Myc, Ctnnb1 (encoding the β-catenin protein), Ccnd1 (encoding the Cyclin D1 protein), Mki67 (encoding the Ki-67 protein), and Pcna in the lungs of mice treated with urethane and HDM compared to mice treated with urethane and VEH or HI-HDM (Fig. 1J). Tumor development was similar in male and female mice (Supplemental Fig. 1B–C). No pleural invasion or distant metastases into other organs were observed in any of the groups (data not shown).

Because inflammation can promote all stages of tumor development, including tumor growth and progression [47], we further evaluated lung inflammation in the different groups. The cellularity in the broncho-alveolar lavage fluid (BALF) was significantly increased in mice treated with urethane and HDM as compared to mice treated with urethane and VEH (Supplemental Fig. 1D–E). Monocytes/macrophages followed by lymphocytes, neutrophils, and eosinophils were the predominant cellular infiltrates in the BALF of HDM-treated mice. HI-HDM-treated mice had a significantly decreased BALF total cell count and showed a reduced trend in BALF differential cell counts (i.e., monocytes/macrophages, lymphocytes, neutrophils, and eosinophils) as compared to HDM-treated mice (Supplemental Fig. 1D–E). However, as previously reported by others [48], heat treatment did not completely abolish the effects of HDM, implying the role of heat-insensitive components in HDM extracts (e.g., heat-insensitive proteases and/or carbohydrates [31, 48]) in the increased BALF cellularity upon HDM exposure. To evaluate the potential role of these different immune cell types in the tumor-promoting effect of HDM, we plotted the BALF total and differential cell counts versus the tumor multiplicity for each mouse of the three experimental groups. Linear regression analyses showed a positive correlation between the number of monocytes/macrophages in the BALF and the tumor multiplicity in mice treated with urethane and HDM but not with urethane and HI-HDM or VEH (Supplemental Fig. 1F). No correlation was found for the other subsets of immune cells in the BALF (data not shown). To evaluate the potential contribution of adaptive immunity to the tumor-promoting effect of HDM, we treated Rag1 KO mice, which lack mature T and B cells, with urethane and with HDM or VEH as described for WT mice in Fig. 1A, and compared the number of lung lesions in the two different groups. As observed in WT mice (Fig. 1), we found a significantly higher number of lung lesions in Rag1 KO mice treated with urethane and HDM as compared to Rag1 KO mice treated with urethane and VEH (Supplemental Fig. 1G–H). Collectively, these results indicate that chronic exposure to HDM accelerates the growth of urethane-induced lung tumors in C57BL/6 mice and that heat-sensitive factors in HDM extracts (e.g., HDM-derived proteases) contribute to this effect. In addition, lung inflammation orchestrated mainly by monocytes/macrophages rather than by adaptive immune cells could mediate the tumor-promoting effect of HDM in this model.

Chronic exposure to HDM accelerates LC development and progression in a mutant Kras-driven LC model

Mutated KRAS is the most common driver mutation in patients with NSCLC and confers a poor prognosis [49]. To confirm the data generated in the urethane-induced LC model and evaluate their potential clinical relevance, we employed CCSP^Cre±Kras^G12D± mice (hereafter referred to as Kras^G12D mice), which develop spontaneous lung tumors [50] and mirrored KRAS-mutated human ACs [45]. We treated age- and sex-matched Kras^G12D mice i.n with HDM or VEH for 9 weeks, and evaluated lung inflammation as well as the occurrence of lung tumors in the two experimental groups at 14 weeks of age (Supplemental Fig. 2A). At autopsy, the lungs of HDM-treated Kras^G12D mice were larger and weighed more than those of VEH-treated Kras^G12D mice (Supplemental Fig. 2B–C). The cellularity in the BALF of mice treated with HDM was significantly increased compared to VEH-treated mice (Supplemental Fig. 2D). At this time point, both HDM- and VEH-treated Kras^G12D mice developed predominantly alveolar/bronchiolar hyperplasia as shown in ROI#1 (Supplemental Fig. 2E) and fewer ADs and ACs. As observed in the urethane-induced LC model, chronic i.n instillation of HDM significantly increased the tumor multiplicity and the tumor area in Kras^G12D mice as compared to VEH-treated mice (Supplemental Fig. 2E-G). The tumor-promoting effect of HDM was observed in a sex-independent manner and was similar in single- and co-housed Kras^G12D mice (data not shown).

To assess the effect of HDM on lung tumor progression and to evaluate the contribution of heat-sensitive factors in HDM extracts in this model, we treated another cohort of Kras^G12D mice i.n with HDM, HI-HDM, or VEH for 9 weeks, let the tumors grow for an additional 4 weeks in absence of i.n treatment and determined the number and subtype of lung tumors in the three experimental groups at 18 weeks of age (Fig. 2A). VEH-treated mice gained weight during the entire protocol whereas mice treated with HDM, and to a lesser degree with HI-HDM, lost weight during the second half of the follow-up period (Fig. 2B). HDM-treated mice had also a decreased survival compared to mice treated with HI-HDM or with VEH in which none of the mice died during the experiment (Fig. 2C). Interestingly, the cellularity in the BALF of mice treated with HDM, and to a lower extent with HI-HDM, remained significantly higher than in VEH-treated mice despite the absence of i.n treatment during the last 4 weeks of the protocol (Fig. 2D). In addition, histological analysis of H&E-stained lung sections revealed the presence of dense perivascular and peribronchial mononuclear inflammatory infiltrates in the lungs of HDM-treated mice (Fig. 2E), with particularly large numbers of macrophages as shown in ROI#1 (Fig. 2F). These inflammatory features were observed to a lesser degree in the lungs of mice treated with HI-HDM and were almost absent in the lungs of VEH-treated mice (Fig. 2E and Supplemental Fig. 2H). At this time point, Kras^G12D mice presented all stages of lung tumor development, from hyperplasia to ACs (Supplemental Fig. 2I). Some tumors in HDM-treated mice demonstrated invasive features, such as invasion of the bronchial lumen and stromal desmoplasia as shown in ROI#2 (Fig. 2F). However, no metastasis was observed in the pleural cavity or distant organs such as the liver, brain, pancreas, and spleen in any of the three experimental groups of mice (data not shown). Mice treated with HDM, but not with HI-HDM, had significantly increased tumor multiplicity and tumor area as compared to mice treated with VEH (Fig. 2G–H). In the three experimental groups, the predominant type of lung lesion was grade 1 (i.e., EH and AAH), followed by the appearance of grade 2 (i.e., ADs) and grade 3 (i.e., ACs) lesions (Fig. 2I, Supplemental Fig. 2I). Interestingly, HDM-treated mice developed significantly less low-grade (i.e., grade 1) but more high-grade (i.e., grades 2 and 3) lesions than VEH-treated mice. This was not observed in mice treated with HI-HDM in which no significant differences were found except for grade 1 lesions as compared to VEH- or HDM-treated mice. However, it is possible that the differences in grade 2 and 3 lesions for HI-HDM-treated mice would have been significant with a higher number of mice per group as increasing the sample size increases statistical power. Collectively, these results suggest that chronic exposure to HDM accelerates the progression of lung lesions from hyperplasia to AD and AC in a Kras^G12D-driven mouse model and that heat-sensitive factors in HDM extracts contribute to this effect.

HDM activates the NLRP3/IL-1β signaling pathway in macrophages

Recent studies suggest that activation of the NLRP3 inflammasome and the resulting increase in IL-1β production are associated with tumor progression in various types of cancer, including LC [51]. Therefore, we evaluated the potential activation of the NLRP3/IL-1β signaling pathway in the lungs of Kras^G12D mice treated with HDM, HI-HDM, or VEH. We detected a strong increase in NLRP3 expression (Fig. 3A–B) and caspase-1 cleavage (Fig. 3A, C) as well as increased production of mature IL-1β by immunoblotting (Fig. 3A, D) and by enzyme-linked immunosorbent assay (ELISA) (Fig. 3E) in lung tissue homogenates of Kras^G12D mice treated with HDM, and to a lesser extent with HI-HDM, compared to those of VEH-treated mice. The fact that these parameters remained significantly elevated in the lungs of HDM-treated mice four weeks after the last i.n challenge is consistent with the increased cellularity in the BALF (Fig. 2D) and the inflammatory features observed in the lungs of these mice (Fig. 2E–F ROI#1), and suggest a prolonged activation of the NLRP3/IL-1β signaling pathway by HDM.

Because macrophages are one of the major cell types that express NLRP3 and produce IL-1β [52], we next evaluated by flow cytometry the effect of chronic i.n instillation of HDM on macrophages in the lungs of Kras^G12D mice at the 14-week-old time point, which precedes the development of advanced lung lesions. We observed a significant increase in the frequencies and the absolute numbers of macrophages (identified as CD11b⁺CD11c^–F4/80⁺ cells as previously described [53, 54]) and macrophages expressing high intracellular levels of pro-IL-1β (Fig. 3I–K) in the lungs of HDM-treated mice as compared to those of VEH-treated mice (Fig. 3F–H, Supplemental Fig. 3A). In addition, the vast majority of the cells in the BALF of HDM-treated mice were positive for the pan-myeloid marker CD11b (Supplemental Fig. 3B–D) and expressed more pro-IL-1β than cells from VEH-treated mice (Supplemental Fig. 3E–G). Interestingly, HDM also induced the accumulation of CD11b⁺ cells expressing high (hi) or intermediate (int) levels of Gr-1 and resembling myeloid-derived suppressor cells (MDSCs, identified as CD11b⁺Gr-1^hi cells in lung tissues and CD11b⁺Gr-1^intF4/80⁺ cells in the BALF) (Fig. 3L–N, Supplemental Fig. 3H–J), and of CD11b⁺ cells expressing programmed cell death protein 1 (PD-1, identified as CD11b⁺PD-1⁺ cells in lung tissues) (Fig. 3O–Q, Supplemental Fig. 3K–M), which are both known to inhibit anti-tumor immunity and to promote tumor development [55, 56]. Collectively, these data suggest that HDM could accelerate lung tumor progression by activating the NLRP3/IL-1β signaling pathway and by creating a pro-tumor lung microenvironment rich in IL-1β⁺-macrophages, MDSCs, and PD-1⁺-myeloid cells.

To determine whether HDM directly activates the NLRP3/IL-1β signaling pathway in macrophages, we conducted in vitro assays with primary bone marrow-derived macrophages (BMDMs) and with the RAW 264.7 mouse macrophage-like cell line. NLRP3 inflammasome activation requires 2 signals: the priming signal (signal 1), provided by endogenous cytokines and microbial components (e.g., LPS), leads to the activation of nuclear factor-kappa B (NF-κB), and the upregulation of NLRP3 and pro-IL-1β expression; and the activation signal (signal 2), provided by various cellular events and stimuli (e.g., ATP), leads to NLRP3 inflammasome activation and the cleavage of pro-IL-1β into bioactive IL-1β [52]. First, we isolated BMDMs from WT C57BL/6 mice and stimulated them for 24 h with increasing concentrations of HDM or with LPS at the high dose of 100 ng/mL. ATP was added to each well for the last hour of culture and IL-1β secretion in the supernatants was measured by ELISA (Supplemental Fig. 4A). HDM concentration-dependently stimulated IL-1β production by BMDMs up to a level comparable to that obtained with LPS (Fig. 4A). In line with these results and those generated in lung tissues (Fig. 3, A–E), HDM also concentration-dependently stimulated gene expression of Il1b and Nlrp3, but not Nlrp1, Nlrc4, Nlrp6, or Nlrp12 in RAW 264.7 macrophages (Fig. 4B–C). Next, we isolated BMDMs from Nlrp3 and Casp1 KO mice and found that these cells have significantly reduced IL-1β production after stimulation with HDM (Fig. 4D, Supplemental Fig. 4A). BMDMs isolated from WT and Il1b KO mice were used as positive and negative controls, respectively. In contrast, the inflammasome-independent cytokine tumor necrosis factor (TNF) was secreted normally by BMDMs isolated from all three KO mice and stimulated with HDM (Fig. 4E). We obtained similar results by pre-treating WT BMDMs with specific inhibitors of the NLRP3 inflammasome (MCC950) [35] and caspase-1 (VX-765) [57] before HDM stimulation (Supplemental Fig. 4B–C). In agreement with the data generated in lung tissues (Fig. 3A–E), HI-HDM induced significantly lower amounts of IL-1β in BMDM culture supernatants as compared to proteolytically active HDM (Fig. 4F), as well as lower expression levels of NLRP3 and pro-IL-1β in BMDM lysates (Fig. 4G). Together, these data indicate that NLRP3 and caspase-1 are required for HDM-induced IL-1β production by murine macrophages and that heat-sensitive factors in HDM extracts are contributing to this effect.

Finally, we tested whether other common environmental allergens could also induce IL-1β production by macrophages and compared the effect of Dermatophagoides pteronyssinus (DP; the HDM species used in this study), Dermatophagoides farinae (DF; the second most prevalent HDM species), German cockroach (CR), ragweed pollen (RW), Candida albicans (CA) and Alternaria alternata (AA) stimulation of BMDMs. Under our experimental conditions (Supplemental Fig. 4A), only DP and to a lesser degree DF and CR triggered IL-1β production by BMDMs (Supplemental Fig. 4D). Interestingly, chronic i.n instillation of DF, but not ovalbumin (OVA), also promoted lung tumor development in Kras^G12D mice (Supplemental Fig. 5). This finding is consistent with the lack of effect of OVA in a urethane-induced LC model [58] and may be imputed to the innocuity of OVA as an antigen.

Neutralization of NLRP3, IL-1β, or CCL2 inhibits the tumor-promoting effect of HDM

The role of chronic inflammation in fueling Kras-driven LC has been well documented [59]. Because our data indicate that HDM activates the NLRP3 inflammasome in macrophages and induces IL-1β secretion in the lungs, we hypothesized that the NLRP3/IL-1β signaling pathway is the main driver of LC progression in response to chronic HDM exposure in our mouse models. To test this hypothesis, we first evaluated the effect of blocking the NLRP3 inflammasome by treating Kras^G12D mice i.n with HDM or VEH and i.p with MCC950, a potent and selective NLRP3 inhibitor [35] (Supplemental Fig. 6A). At 18 weeks of age, the tumor multiplicity in mice treated with HDM and MCC950 was not significantly different compared to that observed in mice treated with VEH and MCC950 (Supplemental Fig. 6B–C). In addition, both groups of mice had similar percentages of low- and high-grade lesions (Supplemental Fig. 6D). Next, we treated another cohort of Kras^G12D mice treated i.n with HDM or VEH and i.p with an anti-IL-1β Ab or the isotype control Ab and determined the occurrence of lung tumors in the four experimental groups (Fig. 5A, Supplemental Fig. 6A). Although, as previously reported by others, IL-1β neutralization did not affect spontaneous tumor formation in Kras^G12D mice [60], it almost completely abolished the tumor-promoting effect of HDM (Fig. 5A–B). Mice treated with HDM and anti-IL-1β Ab had more grade 1 but fewer grade 2 lesions and also tended to have fewer grade 3 lesions than mice treated with HDM and isotype control Ab (Fig. 5C).

To evaluate the effect of IL-1β blockade in the urethane-induced LC model, we treated WT and Il1b KO mice i.p with urethane and i.n with HDM or VEH following the protocol shown in Fig. 1A. In line with the effect of IL-1β neutralization in Kras^G12D mice, the tumor multiplicity and the tumor area were strongly reduced in Il1b KO mice treated with urethane and HDM as compared to WT mice that received the same treatments and were not significantly different from the tumor multiplicity and tumor area of Il1b KO mice treated with urethane and VEH (Fig. 5D, F–G). Interestingly, Il1b KO mice treated with urethane and HDM only developed ADs, and none of them developed ACs as observed in WT mice treated with urethane and HDM (Fig. 5E).

Next, we hypothesized that inhibition of CCL2, a key IL-1β-target gene and a main inflammatory chemokine attracting primarily monocytes and macrophages to sites of inflammation [61], would recapitulate the effects of IL-1β blockade in Kras^G12D mice. CCL2 level in the BALF was previously found to correlate with increased macrophage numbers and with lung tumor development in Kras^G12D mice [62]. CCL2 levels were increased in the BALF of Kras^G12D mice treated with HDM, but not with HI-HDM (Supplemental Fig. 7A), and this effect was inhibited by IL-1β blockade (Supplemental Fig. 7B). In line with our hypothesis, CCL2 neutralization almost completely abolished the effect of HDM on tumor development and progression (Fig. 5A–C, Supplemental Fig. 6A). Collectively, these data suggest that the lung tumor-promoting effect of HDM is mostly mediated by the recruitment of macrophages into the lungs and by the activation of the NLRP3/IL-1β signaling pathway in these cells.

IL-1β blockade reverses the effects of HDM on the lung tumor microenvironment (TME)

Based on the data presented above, we hypothesized that chronic HDM exposure changes the lung TME and makes it conducive to tumor growth by triggering IL-1β-mediated inflammation. To test this hypothesis, we treaded Kras^G12D mice i.n with VEH or HDM alone or i.n with HDM and i.p with a neutralizing anti-IL-1β Ab, and performed H&E, IHC, and multiplex immunofluorescence (mIF) staining (Fig. 6, Supplemental Fig. 8A–E). In line with the flow cytometry data (Fig. 3F–H), we found a marked increase in F4/80⁺ cells in the lungs of HDM-treated mice as compared to those of VEH-treated mice (Fig. 6B, E–F). As previously described in the Kras^G12D-driven LC model [62], we only observed a few intratumoral F4/80⁺ cells, and the vast majority of these cells were found in the parenchymal lung tissue and around the tumors (Fig. 6E). Interestingly, the increased infiltration of F4/80⁺ cells induced by HDM was almost completely abolished by the anti-IL-1β Ab (Fig. 6B, F). Histological analysis revealed that lung tumors of HDM-treated mice express cytokeratins (PanCK), supporting their epithelial origin, and have increased Ki-67 immunoreactivity, indicating their higher proliferating activity, as compared to lung tumors of VEH-treated mice (Fig. 6B, E ROI#2, G). In line with our hypothesis, the anti-IL-1β Ab inhibited the increase in Ki-67⁺ cells in tumors of HDM-treated mice (Fig. 6B, G). Similar to the lung ACs seen in WT mice treated with urethane and HDM (Fig. 1G), strong nuclear staining for TTF-1 was observed in tumor cells of grade 3 lesions from HDM-treated Kras^G12D mice (Fig. 6D, Supplemental Fig. 8F). Collectively, these data indicate that chronic exposure to HDM induces a lung TME rich in macrophages and increases tumor cell proliferation in an IL-1β-dependent manner.

Budesonide treatment inhibits the pro-tumorigenic effect of HDM

Because IL-1β and CCL2 contribute to the development of CLI, which may mediate the link between chronic exposure to HDM in asthmatic patients and an increased risk of developing LC [8, 10], we tested in a last set of experiments the effect of budesonide, an ICS commonly prescribed to reduce airway inflammation in asthmatic and COPD patients [63]. In addition to its anti-inflammatory effect, budesonide was shown to have anti-proliferative properties [64] and may decrease the risk of developing LC in asthmatic and COPD patients [65, 66]. Consistent with its chemopreventive effect in different mouse models of LC [67‐69], budesonide i.n treatment inhibited the tumor-promoting effect of HDM in Kras^G12D mice (Fig. 7A–C). Lastly, we determined the effect of budesonide treatment on NLRP3 activation and IL-1β production using BMDMs. Budesonide strongly inhibited HDM-induced Il1b mRNA (Fig. 7D) and pro-IL-1β expression (Fig. 7E) as well as mature IL-1β secretion (Fig. 7F), even though budesonide only slightly inhibited HDM-induced NLRP3 upregulation (Fig. 7E) at the low-dose of 1 nM and at the time point chosen in this assay. Overall, these findings are in agreement with previous studies using budesonide [70, 71] or other ICS [72, 73] and suggest that ICS treatment decreases lung tumor development in mice and might reduce the risk of developing LC in asthmatic and COPD patients, at least in part, by inhibiting the NLRP3/IL-1β signaling pathway in lung macrophages.

Discussion

Despite recent advances in the prevention and treatment of LC, the exact mechanisms by which CLI promotes LC development remain unclear. To fill this gap of knowledge, we tested the hypothesis that chronic exposure to HDM, a major cause of allergic asthma, can provoke CLI and consequently, accelerate the development of LC in mice. We report here for the first time that the pathological effect of HDM is not limited to the induction of allergic lung inflammation as it occurs in asthma, and that chronic exposure to HDM also accelerates LC development and progression in two different mouse models of LC.

Mechanistically, we identified that the chronic activation of the NLRP3/IL-1β signaling pathway is a possible underlying mechanism (see Supplemental Fig. 9 for the proposed model) as neutralization of NLRP3 or IL-1β, almost completely abolished the LC-promoting effect of HDM. Interestingly, NLRP3 activation, IL-1β production, and the pro-tumorigenic effect of HDM were significantly decreased but not completely abolished by heat treatment of the HDM extract. As published by others using a similar heat-inactivation method and HDM extract from Greer Laboratories it could potentially be due to the remaining protease activity in the HI-HDM extract (28% protease activity remaining after 1 h at 95ºC [31]). It is also possible that both heat-sensitive and -insensitive factors contributed to the observed effects. For example, HDM-derived proteases such as Der p1 (D. pteronyssinus allergen 1) and Der f1 (D. farinae allergen 1) were shown to directly activate NLRP3 in human bronchial epithelial cells and to induce caspase-1-mediated IL-1β secretion [74, 75]. LPS in HDM extracts could also contribute to NLRP3 activation and IL-1β production [52], and chronic exposure to high doses of LPS was shown to promote lung tumorigenesis in the nicotine-derived nitrosamine ketone (NNK)- and benzo[a]pyrene (B[a]P)-induced LC models [76, 77]. In addition, chitin present in HDM extracts and chitosan, which is derived from deacetylated chitin were shown to activate NLRP3 and induce IL-1β production [48, 78, 79], and may therefore contribute to the effects observed in response to HDM exposure. However, the biochemical complexity of HDM makes challenging investigations on the contribution of a given component to the observed effects, and further studies are required to identify the active component(s) in HDM responsible for its pro-tumorigenic effect. In addition, our results suggest that HDM predominantly activates the NLRP3 inflammasome in macrophages, but we cannot exclude that other cell types such as neutrophils and/or eosinophils also contribute to IL-1β secretion and to the tumor-promoting effect of HDM.

Interestingly, the tumor-promoting effect of HDM was more pronounced in the Kras^G12D-driven model (effect size of ~ 4–5/VEH group) than in the urethane-induced model (effect size of ~ 2–3/VEH group). A potential explanation could be that urethane-induced tumors in WT mice carry mostly Kras^Q61L/R mutations [80, 81], which could potentially be less sensitive to the effect of lung inflammation and to a proinflammatory TME than the Kras^G12D mutation [59, 82]. In support of this hypothesis, a recent study shows that IL-1β blockade decreases Kras^G12D-induced lung tumorigenesis by shifting the immunosuppressive TME to an antitumor phenotype, possibly via modulating the NF-κB and signal transducer and activator of transcription 3 (STAT3) pathways [83]. Thus, chronic activation of the NLRP3/caspase-1/IL-1β signaling pathway by HDM may mediate a positive feedback loop that amplifies oncogenic Kras^G12D activity. Our results, therefore, suggest that the effect of HDM varies in presence of different driver mutations, and further studies are needed to test the effects of HDM in other oncogene-driven LC models (e.g., epidermal growth factor receptor (EGFR)-mutant LC model as EGFR is one of the most frequently mutated driver gene in LC, particularly in non-smokers [84, 85]).

The relationship between allergic diseases and cancer is a very controversial topic, widely discussed during the last decades, which has led to the emerging interdisciplinary field of AllergoOncology [86]. Indeed, some epidemiological studies have demonstrated an inverse association between allergy and cancer, but others have reached neutral conclusions or have indicated a positive role of allergy in the development of cancer. Epidemiological studies are difficult to perform in this field because of the many confounding factors. For example, asthma was found to be protective against the risk of developing LC in some studies potentially because asthmatics tend to be non-smokers [87]. Asthma’s relationship to LC is still controversial, however, the recent discovery of different asthma endotypes Th2/Th17-low and Th2/Th17-predominant, in which IL-1β plays a critical role [88], may explain this controversy and help the design of future epidemiological studies that will take into account the heterogeneity of asthma. Another potential reason why some epidemiological studies did not identify a positive association between asthma and the risk of LC could be because most asthmatic patients are treated with an ICS, which has anti-inflammatory and anti-proliferative properties, and may decrease the risk of developing LC [65, 66, 89]. Indeed, in a recent study including 75,307 participants, adults with asthma had a 2.8-fold increased risk of developing LC, and treatment with ICS was associated with a 56% risk reduction [11], suggesting that an inflammatory response mediates the link between asthma and LC. In agreement with a previous study [70], we found that budesonide inhibits NLRP3 and decreases IL-1β production by macrophages, which could explain, at least in part, its anti-tumor effect.

Conclusions

Our study demonstrates a causal link between chronic exposure to HDM and the acceleration of lung tumorigenesis in mice. These data indicate that the effect of long-term exposure to HDM goes beyond the induction of asthma and allergic lung inflammation, and increases the risk of developing LC in susceptible animals. Thus, one can speculate that human subjects chronically exposed to HDM, who do not develop asthma and therefore do not take ICS, are more vulnerable to the LC-promoting effect of HDM. However, further studies are needed to test the effects of naturally occurring HDM exposure, which includes whole mite bodies, feces, and associated bacteria, and determine whether long-term exposure to HDM represents an environmental risk factor for LC in humans.

Acknowledgements

We thank Dr. Seon Hee Chang (The University of Texas MD Anderson Cancer Center) for providing the initial breeding pairs of CCSP^Cre and LSL-Kras^G12D mice; Dr. Wai Wilson Cheung, Dr. Robert Mak, and Dr. Hal Hoffman (UCSD) for providing the initial breeding pairs of Il1b KO mice; Dr. Richard Flavell (Yale University) for providing the initial breeding pairs of Casp1 KO mice; Dr. Zbigniew Mikulski (La Jolla Institute for Immunology) for providing training with QuPath software; Jennifer Santini at the UCSD School of Medicine Microscopy Core, funded by NIH Grant NINDS P30 NS047101 through the NINDS, for technical assistance with whole slide scanning; and the Tissue Technology Shared Resources at the UCSD Moores Cancer Center, supported by the NCI CCSG Grant P30CA23100.

Declarations

All the animal studies were conducted in accordance with protocols approved by the UCSD Institutional Animal Care and Use Committee (IACUC) and following the ARRIVE guidelines.

Not applicable.

Competing interests

HMH has received speaking fees from Novartis, consulting fees from Novartis, SOBI, Regeneron, and IFM, and research funds from Glaxo Wellcome, Vertex, Burroughs Wellcome, and Jecure. ML, ZA, HS, and DS are employees, shareholders, and/or option holders at Cell IDx. The other authors declare that they have no competing interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.CrossRef

Gorlova OY, Zhang Y, Schabath MB, Lei L, Zhang Q, Amos CI, et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int J Cancer. 2006;118(7):1798–804.CrossRef

Malhotra J, Malvezzi M, Negri E, la Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889–902.CrossRef

Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007;176(3):285–90.CrossRef

Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol. 2014;5(4):660–6.CrossRef

García Sanz MT, González Barcala FJ, Alvarez Dobaño JM, Valdés CL. Asthma and risk of lung cancer. Clin Transl Oncol. 2011;13(10):728–30.CrossRef

Brown DW, Young KE, Anda RF, Giles WH. Asthma and risk of death from lung cancer: NHANES II Mortality Study. J Asthma. 2005;42(7):597–600.CrossRef

Qu YL, Liu J, Zhang LX, Wu CM, Chu AJ, Wen BL, et al. Asthma and the risk of lung cancer: a meta-analysis. Oncotarget. 2017;8(7):11614–20.CrossRef

10.

Santillan AA, Camargo CA, Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control. 2003;14(4):327–34.CrossRef

11.

Woo A, Lee SW, Koh HY, Kim MA, Han MY, Yon DK. Incidence of cancer after asthma development: 2 independent population-based cohort studies. J Allergy Clin Immunol. 2021;147(1):135–43.CrossRef

12.

Gomes M, Teixeira AL, Coelho A, Araújo A, Medeiros R. The role of inflammation in lung cancer. Adv Exp Med Biol. 2014;816:1–23.CrossRef

13.

Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8(4):605–15.CrossRef

14.

Gregory LG, Lloyd CM. Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 2011;32(9):402–11.CrossRef

15.

Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ, et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care Med. 2004;169(3):378–85.CrossRef

16.

Chan TK, Loh XY, Peh HY, Tan WNF, Tan WSD, Li N, et al. House dust mite-induced asthma causes oxidative damage and DNA double-strand breaks in the lungs. J Allergy Clin Immunol. 2016;138(1):84–96.e1.CrossRef

17.

Chan TK, Tan WSD, Peh HY, Wong WSF. Aeroallergens Induce Reactive Oxygen Species Production and DNA Damage and Dampen Antioxidant Responses in Bronchial Epithelial Cells. J Immunol. 2017;199(1):39–47.CrossRef

18.

Sundaram K, Mitra S, Gavrilin MA, Wewers MD. House Dust Mite Allergens and the Induction of Monocyte Interleukin 1β Production That Triggers an IκBζ-Dependent Granulocyte Macrophage Colony-Stimulating Factor Release from Human Lung Epithelial Cells. Am J Respir Cell Mol Biol. 2015;53(3):400–11.CrossRef

19.

Dai X, Sayama K, Tohyama M, Shirakata Y, Hanakawa Y, Tokumaru S, et al. Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes. J Allergy Clin Immunol. 2011;127(3):806-14.e1-4.CrossRef

20.

Abu Khweek A, Joldrichsen MR, Kim E, Attia Z, Krause K, Daily K, et al. Caspase-11 regulates lung inflammation in response to house dust mites. Cell Immunol. 2021;370:104425.CrossRef

21.

Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100(5):2645–50.CrossRef

22.

Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25(3):387–408.CrossRef

23.

Gottschlich A, Endres S, Kobold S. Can we use interleukin-1β blockade for lung cancer treatment? Transl Lung Cancer Res. 2018;7(Suppl 2):S160–4.CrossRef

24.

Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–42.CrossRef

25.

Schenk KM, Reuss JE, Choquette K, Spira AI. A review of canakinumab and its therapeutic potential for non-small cell lung cancer. Anticancer Drugs. 2019;30(9):879–85.CrossRef

26.

Garrido P, Pujol JL, Kim ES, Lee JM, Tsuboi M, Gómez-Rueda A, et al. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncol. 2021;17(12):1459–72.CrossRef

27.

Zhang J, Veeramachaneni N. Targeting interleukin-1β and inflammation in lung cancer. Biomark Res. 2022;10(1):5.CrossRef

28.

Wong CC, Baum J, Silvestro A, Beste MT, Bharani-Dharan B, Xu S, et al. Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. Cancer Res. 2020;80(24):5597–605.CrossRef

29.

Li H, Cho SN, Evans CM, Dickey BF, Jeong JW, DeMayo FJ. Cre-mediated recombination in mouse Clara cells. Genesis. 2008;46(6):300–7.CrossRef

30.

Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243–8.CrossRef

31.

Post S, Nawijn MC, Hackett TL, Baranowska M, Gras R, van Oosterhout AJM, et al. The composition of house dust mite is critical for mucosal barrier dysfunction and allergic sensitisation. Thorax. 2012;67(6):488–95.CrossRef

32.

Miller YE, Dwyer-Nield LD, Keith RL, Le M, Franklin WA, Malkinson AM. Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections. Cancer Lett. 2003;198(2):139–44.CrossRef

33.

Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–8.CrossRef

34.

Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, et al. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther. 2017;16(2):312–22.CrossRef

35.

Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–55.CrossRef

36.

Kalidhindi RSR, Ambhore NS, Sathish V. Cellular and Biochemical Analysis of Bronchoalveolar Lavage Fluid from Murine Lungs. Methods Mol Biol. 2021;2223:201–15.CrossRef

37.

Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.CrossRef

38.

Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 2004;64(7):2307–16.CrossRef

39.

DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009;4(7):1064–72.CrossRef

40.

van Batenburg AA, van Oosterhout MFM, Knoppert SN, Kazemier KM, van der Vis JJ, Grutters JC, et al. The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis. Front Med (Lausanne). 2021;8:736485.CrossRef

41.

de Jong PR, Taniguchi K, Harris AR, Bertin S, Takahashi N, Duong J, et al. ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation. Nat Commun. 2016;7:11551.CrossRef

42.

Lancelin W, Guerrero-Plata A. Isolation of mouse lung dendritic cells. J Vis Exp. 2011;57:3563.

43.

Lee J, Kim TH, Murray F, Li X, Choi SS, Broide DH, et al. Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma. Proc Natl Acad Sci U S A. 2015;112(5):1529–34.CrossRef

44.

Gurley KE, Moser RD, Kemp CJ. Induction of Lung Tumors in Mice with Urethane. Cold Spring Harb Protoc. 2015;2015(9):077446.CrossRef

45.

Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev. 2005;19(6):643–64.CrossRef

46.

Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36(1):8–16.CrossRef

47.

Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41.CrossRef

48.

Kim LK, Morita R, Kobayashi Y, Eisenbarth SC, Lee CG, Elias J, et al. AMCase is a crucial regulator of type 2 immune responses to inhaled house dust mites. Proc Natl Acad Sci U S A. 2015;112(22):E2891–9.CrossRef

49.

Villaruz LC, Socinski MA, Cunningham DE, Chiosea SI, Burns TF, Siegfried JM, et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. Cancer. 2013;119(12):2268–74.CrossRef

50.

Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol. 2009;40(4):443–53.CrossRef

51.

Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol Cancer. 2018;17(1):158.CrossRef

52.

Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20(13):3328.CrossRef

53.

Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GRS, Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol. 2013;49(4):503–10.CrossRef

54.

Zaynagetdinov R, Sherrill TP, Kendall PL, Segal BH, Weller KP, Tighe RM, et al. Identification of myeloid cell subsets in murine lungs using flow cytometry. Am J Respir Cell Mol Biol. 2013;49(2):180–9.CrossRef

55.

Dysthe M, Parihar R. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1224:117–40.CrossRef

56.

Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, Wang Q, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5(43):eaay1863.CrossRef

57.

Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–16.CrossRef

58.

Doris K, Karabela SP, Kairi CA, Simoes DC, Roussos C, Zakynthinos SG, et al. Allergic inflammation does not impact chemical-induced carcinogenesis in the lungs of mice. Respir Res. 2010;26(11):118.CrossRef

59.

Kitajima S, Thummalapalli R, Barbie DA. Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. Semin Cell Dev Biol. 2016;58:127–35.CrossRef

60.

McLoed AG, Sherrill TP, Cheng DS, Han W, Saxon JA, Gleaves LA, et al. Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer. Cell Rep. 2016;16(1):120–32.CrossRef

61.

Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–26.CrossRef

62.

Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene. 2006;25(14):2105–12.CrossRef

63.

Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin. 2007;23(8):1867–78.CrossRef

64.

Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol. 2002;71(1):9–15.CrossRef

65.

Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, Lynd LD. Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. Eur Respir J. 2019;53(6):1801257.CrossRef

66.

Wang IJ, Liang WM, Wu TN, Karmaus WJJ, Hsu JC. Inhaled corticosteroids may prevent lung cancer in asthma patients. Ann Thorac Med. 2018;13(3):156–62.CrossRef

67.

Yao R, Wang Y, Lemon WJ, Lubet RA, You M. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene. 2004;23(46):7746–52.CrossRef

68.

Balansky R, Ganchev G, Iltcheva M, Steele VE, de Flora S. Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine. Int J Cancer. 2010;126(5):1047–54.

69.

Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 1997;57(24):5489–92.

70.

Dong L, Zhu YH, Liu DX, Li J, Zhao PC, Zhong YP, et al. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice. J Immunol Res. 2019;2019:7264383.CrossRef

71.

Ju YN, Yu KJ, Wang GN. Budesonide ameliorates lung injury induced by large volume ventilation. BMC Pulm Med. 2016;16(1):90.CrossRef

72.

Guan M, Ma H, Fan X, Chen X, Miao M, Wu H. Dexamethasone alleviate allergic airway inflammation in mice by inhibiting the activation of NLRP3 inflammasome. Int Immunopharmacol. 2020;78:106017.CrossRef

73.

Yang JW, Mao B, Tao RJ, Fan LC, Lu HW, Ge BX, et al. Corticosteroids alleviate lipopolysaccharide-induced inflammation and lung injury via inhibiting NLRP3-inflammasome activation. J Cell Mol Med. 2020;24(21):12716–25.CrossRef

74.

Kim SR, Park HJ, Lee KB, Kim HJ, Jeong JS, Cho SH, et al. Epithelial PI3K-δ Promotes House Dust Mite-Induced Allergic Asthma in NLRP3 Inflammasome-Dependent and -Independent Manners. Allergy Asthma Immunol Res. 2020;12(2):338–58.CrossRef

75.

Tsai YM, Chiang KH, Hung JY, Chang WA, Lin HP, Shieh JM, et al. Der f1 induces pyroptosis in human bronchial epithelia via the NLRP3 inflammasome. Int J Mol Med. 2018;41(2):757–64.

76.

Melkamu T, Qian X, Upadhyaya P, O’Sullivan MG, Kassie F. Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer. Vet Pathol. 2013;50(5):895–902.CrossRef

77.

Huang L, Duan S, Shao H, Zhang A, Chen S, Zhang P, et al. NLRP3 deletion inhibits inflammation-driven mouse lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide. Respir Res. 2019;20(1):20.CrossRef

78.

Bueter CL, Lee CK, Wang JP, Ostroff GR, Specht CA, Levitz SM. Spectrum and mechanisms of inflammasome activation by chitosan. J Immunol. 2014;192(12):5943–51.CrossRef

79.

Arae K, Morita H, Unno H, Motomura K, Toyama S, Okada N, et al. Chitin promotes antigen-specific Th2 cell-mediated murine asthma through induction of IL-33-mediated IL-1β production by DCs. Sci Rep. 2018;8(1):11721.CrossRef

80.

Li S, MacAlpine DM, Counter CM. Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nat Commun. 2020;11(1):1800.CrossRef

81.

Westcott PMK, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature. 2015;517(7535):489–92.CrossRef

82.

Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386.CrossRef

83.

Yuan B, Clowers MJ, Velasco WV, Peng S, Peng Q, Shi Y, et al. Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer. JCI Insight. 2022;7(11):e157788.CrossRef

84.

Ren JH, He WS, Yan GL, Jin M, Yang KY, Wu G. EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis. Environ Mol Mutagen. 2012;53(1):78–82.CrossRef

85.

Planchard D, Besse B. Lung cancer in never-smokers. Eur Respir J. 2015;45(5):1214–7.CrossRef

86.

della Valle L, Gatta A, Farinelli A, Scarano G, Lumaca A, Tinari N, et al. llergooncology: an expanding research area. J Biol Regul Homeost Agents. 2020;34(2):319–26.

87.

Takiguchi H, Takeuchi T, Niimi K, Tomomatsu H, Tomomatsu K, Hayama N, et al. Proportion and clinical characteristics of non-asthmatic non-smokers among adults with airflow obstruction. PLoS ONE. 2018;13(5):e0196132.CrossRef

88.

Liu W, Liu S, Verma M, Zafar I, Good JT, Rollins D, et al. Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma. J Allergy Clin Immunol. 2017;139(5):1548–1558.e4.CrossRef

89.

Lee CH, Hyun MK, Jang EJ, Lee NR, Kim K, Yim JJ. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. Respir Med. 2013;107(8):1222–33.CrossRef

Titel: Long-term exposure to house dust mites accelerates lung cancer development in mice
verfasst von: Dongjie Wang
Wen Li
Natalie Albasha
Lindsey Griffin
Han Chang
Lauren Amaya
Sneha Ganguly
Liping Zeng
Bora Keum
José M. González-Navajas
Matt Levin
Zohreh AkhavanAghdam
Helen Snyder
David Schwartz
Ailin Tao
Laela M. Boosherhri
Hal M. Hoffman
Michael Rose
Monica Valeria Estrada
Nissi Varki
Scott Herdman
Maripat Corr
Nicholas J. G. Webster
Eyal Raz
Samuel Bertin
Publikationsdatum: 01.12.2023
Verlag: BioMed Central
Erschienen in: Journal of Experimental & Clinical Cancer Research / Ausgabe 1/2023
Elektronische ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-022-02587-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Supplementary Information

Publisher's Note

Background

Materials and methods

Animals

Chemical compounds

Allergen extracts

Intranasal instillations

Urethane-induced LC model

KrasG12D-driven LC model

BALF cellularity analysis

Histological analysis

Immunohistochemistry and immunofluorescence staining

Flow cytometry analysis

Immunoblotting

In vitro macrophage assays

RT-qPCR analysis

ELISA

Graphical illustrations

Statistics

Results

Chronic exposure to HDM accelerates LC development and progression in a urethane-induced LC model

Chronic exposure to HDM accelerates LC development and progression in a mutant Kras-driven LC model

HDM activates the NLRP3/IL-1β signaling pathway in macrophages

Neutralization of NLRP3, IL-1β, or CCL2 inhibits the tumor-promoting effect of HDM

IL-1β blockade reverses the effects of HDM on the lung tumor microenvironment (TME)

Budesonide treatment inhibits the pro-tumorigenic effect of HDM

Discussion

Conclusions

Acknowledgements

Declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher's Note

Supplementary Information

Weitere Artikel der Ausgabe 1/2023

CircGPRC5A enhances colorectal cancer progress by stabilizing PPP1CA and inducing YAP dephosphorylation

Research progress on non-protein-targeted drugs for cancer therapy

Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR

RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia

Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer

RSK3 switches cell fate: from stress-induced senescence to malignant progression

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Update Onkologie

Kras^G12D-driven LC model